218 related articles for article (PubMed ID: 33214693)
1. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
2. TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Al Zoubi MS; Otoum R; Alorjani MS; Al Bashir S; Al Trad B; Abualrja MI; Al-Khatib SM; Al-Batayneh K
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3365-3371. PubMed ID: 33247697
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
4. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
5. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
6. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
7. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.
Lo Iacono M; Buttigliero C; Monica V; Bollito E; Garrou D; Cappia S; Rapa I; Vignani F; Bertaglia V; Fiori C; Papotti M; Volante M; Scagliotti GV; Porpiglia F; Tucci M
Oncotarget; 2016 Mar; 7(12):14394-404. PubMed ID: 26887047
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer.
Zhou J; Lai Y; Peng S; Tang C; Chen Y; Li L; Huang H; Guo Z
Front Oncol; 2022; 12():957404. PubMed ID: 36119488
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
11. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
12. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
Nientiedt C; Endris V; Jenzer M; Mansour J; Sedehi NTP; Pecqueux C; Volckmar AL; Leichsenring J; Neumann O; Kirchner M; Hoveida S; Lantwin P; Kaltenecker K; Dieffenbacher S; Gasch C; Hofer L; Franke D; Tosev G; Görtz M; Schütz V; Radtke JP; Nyarangi-Dix J; Hatiboglu G; Simpfendörfer T; Schönberg G; Isaac S; Teber D; Koerber SA; Christofi G; Czink E; Kreuter R; Apostolidis L; Kratochwil C; Giesel F; Haberkorn U; Debus J; Sültmann H; Zschäbitz S; Jäger D; Duensing A; Schirmacher P; Grüllich C; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2020 Jul; 38(7):637.e17-637.e27. PubMed ID: 32280037
[TBL] [Abstract][Full Text] [Related]
16. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
Gillard M; Lack J; Pontier A; Gandla D; Hatcher D; Sowalsky AG; Rodriguez-Nieves J; Vander Griend D; Paner G; VanderWeele D
Eur Urol Focus; 2019 May; 5(3):433-442. PubMed ID: 29229583
[TBL] [Abstract][Full Text] [Related]
17. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.
van Beek EJAH; Hernandez JM; Goldman DA; Davis JL; McLaughlin K; Ripley RT; Kim TS; Tang LH; Hechtman JF; Zheng J; Capanu M; Schultz N; Hyman DM; Ladanyi M; Berger MF; Solit DB; Janjigian YY; Strong VE
Ann Surg Oncol; 2018 Jul; 25(7):2027-2033. PubMed ID: 29725898
[TBL] [Abstract][Full Text] [Related]
18. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.
Koga Y; Song H; Chalmers ZR; Newberg J; Kim E; Carrot-Zhang J; Piou D; Polak P; Abdulkadir SA; Ziv E; Meyerson M; Frampton GM; Campbell JD; Huang FW
Clin Cancer Res; 2020 Sep; 26(17):4651-4660. PubMed ID: 32651179
[TBL] [Abstract][Full Text] [Related]
20. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]